Tumor Necrosis Factor Receptor Superfamily, Member 7
"Tumor Necrosis Factor Receptor Superfamily, Member 7" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D018127
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.048 D23.050.301.264.894.127 D23.101.100.894.127
|
| Concept/Terms |
Tumor Necrosis Factor Receptor Superfamily, Member 7- Tumor Necrosis Factor Receptor Superfamily, Member 7
- CD27 Antigens
- TNFRSF7 Receptor
- Receptor, TNFRSF7
- T-Cell Activation Antigen
- Activation Antigen, T-Cell
- Antigen, T-Cell Activation
- T Cell Activation Antigen
- Antigen, CD27
- CD27 Antigen
- Antigens, CD27
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Receptor Superfamily, Member 7".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- Tumor Necrosis Factor Receptor Superfamily, Member 7 [D12.776.543.750.705.852.760.048]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Tumor Necrosis Factor Receptor Superfamily, Member 7 [D23.050.301.264.894.127]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Tumor Necrosis Factor Receptor Superfamily, Member 7 [D23.101.100.894.127]
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Receptor Superfamily, Member 7".
This graph shows the total number of publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 7" by people in this website by year, and whether "Tumor Necrosis Factor Receptor Superfamily, Member 7" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 7" by people in Profiles.
-
Tomalka AG, Resto-Garay I, Campbell KS, Popkin DL. In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol. 2018; 9:2552.
-
Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, Simpson LL, Dessain SK. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J Immunol Methods. 2008 Apr 20; 333(1-2):156-66.
-
Leucci E, De Falco G, Onnis A, Cerino G, Cocco M, Luzzi A, Crupi D, Tigli C, Bellan C, Tosi P, Leoncini L, Giordano A. The role of the Cdk9/Cyclin T1 complex in T cell differentiation. J Cell Physiol. 2007 Aug; 212(2):411-5.
-
Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis. 2001 Jan 15; 183(2):197-205.
-
Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol. 2000 Nov 01; 111(1-2):186-94.
-
Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988 Mar 15; 48(6):1671-5.